Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease - Wikidata - wikimedia - TriplyDB

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

http://www.wikidata.org/entity/Q29618681

about

The safety of long-acting ß2-agonists in the treatment of stable chronic obstructive pulmonary disease Stepping down asthma treatment: how and when Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease Ipratropium bromide for stable chronic obstructive pulmonary disease Long-acting beta2-agonists for chronic obstructive pulmonary disease Beclometasone for chronic obstructive pulmonary disease Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease Inhaled corticosteroids for stable chronic obstructive pulmonary disease Combined corticosteroid and long-acting beta 2 -agonist in one inhaler versus placebo for chronic obstructive pulmonary disease Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease Ipratropium bromide for stable chronic obstructive pulmonary disease Inhaled corticosteroids versus long-acting beta2-agonists for chronic obstructive pulmonary disease The effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary disease Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease Inhaled corticosteroids versus long-acting beta 2 -agonists for chronic obstructive pulmonary disease Inhaled corticosteroids versus long acting beta-agonists for chronic obstructive pulmonary disease Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease β(2) -adrenoceptor agonists: current and future direction Efficacy and safety of conventional long acting β2- agonists: systematic review and meta-analysis Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease COPD immunopathology Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA Exacerbations of COPD N-acetylcysteine in COPD: why, how, and when?Mucosal-associated invariant T cells in autoimmunity, immune-mediated diseases and airways disease A rational approach to single, dual and triple therapy in COPD Tiotropium Bromide in Chronic Obstructive Pulmonary Disease and Bronchial Asthma Targeted anti-inflammatory therapeutics in asthma and chronic obstructive lung disease Long-acting muscarinic antagonist + long-acting beta agonist versus long-acting beta agonist + inhaled corticosteroid for COPD: A systematic review and meta-analysis Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life Is COPD associated with increased mortality and morbidity in hospitalized pneumonia? A systematic review and meta-analysis

P2860

Q22305858-C0E42E3E-4A8A-441A-B963-2B9108678669 Q23916999-FC7AA689-D084-4876-AE37-477AA740F448 Q24186411-6374B819-4E5E-4D8D-83D3-525A480237C3 Q24194933-E7A6EC24-1120-4D49-8784-B6E60E621B60 Q24197467-07B92F6D-7424-4CBA-A5C9-6CAA823C8BE5 Q24197535-0951FF2C-DA9C-44CB-A1AB-930F2BE31C5D Q24197853-EF17E3DB-3F1B-4D99-912F-658F4D537FB2 Q24197989-FC5151CF-65BE-4DEC-978D-A872DBDFBBA4 Q24199130-16B154BA-16C6-48DF-AE53-FA3E688CDA2B Q24200331-747D9CC2-0F3C-4179-B123-95A79BCA6EC6 Q24200446-1BA357A1-3E87-49D6-9432-977F77350217 Q24200476-F0D12098-7C1D-4F05-B494-C1F53B3DEB04 Q24202092-DC8283CA-5496-4260-8929-FA6F8A5BD6DF Q24202510-56DD4399-F824-417B-B864-EBEC16963BEA Q24202545-6140CF91-E708-40EA-B807-4E944F38523C Q24202744-C70E3528-9ED8-475D-99B3-574AF1E82AEA Q24234151-B73D8419-7F26-43C8-94B0-566522C1195A Q24234164-5B4EF635-F36B-40C3-BCE2-3287BCD0133F Q24234343-11B77D83-B157-4518-9EAF-C66D94955ADB Q24234493-1197FDB9-BB64-4A4F-A05B-BD04016CD152 Q24235460-3513E3AD-A966-48E7-AD21-372EAD9A3512 Q24236037-D8870C67-606F-40D2-AC6F-5E8905D04E06 Q24243419-D3E1D4C5-D9D7-40C3-9EBA-9E5C89BC9A7A Q24243515-126A8B57-C7A3-4666-9EF9-89A8FE5DD1BE Q24243564-975DEE64-DEA0-4BCE-A446-5DA8EA37131E Q24243613-D7B68DB6-0B84-4FF1-ACDC-1ECE5BCE20F1 Q24604047-97CCE76E-A1D6-42D1-BDC3-61D1EE9C51C1 Q26744161-78503227-B3DF-4A64-A29B-4A1213831C1A Q26745663-FFD875C8-A6E0-4DC0-90E2-8CE0BF4386B3 Q26749575-87469124-695B-49C7-8DB8-A073AEB1BE11 Q26752988-4DE0CB85-149D-4A79-AF8B-FA4D5A070D5C Q26764891-D3C4B51F-DAAC-4BC9-8500-6597B6B95D1D Q26768289-88B2C975-54FF-4A91-8098-EAD95A50B987 Q26771558-DA933C3F-9B1F-4BC2-B8A8-26CC19D6D61E Q26776477-7DF39942-DA31-4575-B34C-A01BFDAD2181 Q26780553-55371BC4-118E-47E8-B095-D28B323C3C22 Q26786229-30779E6B-20AA-41A0-83F1-61FC8FAD661B Q26800134-FA7AE619-1EC6-4BDC-9B2D-4F9DFFD0362E Q26801134-60300DAD-F57F-4DFF-8012-51B1287D1E74 Q26801413-E2076EA9-1FDF-4872-9D6A-CC2555504BF3

P2860

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

http://www.wikidata.org/entity/Q29618681

description

2007 nî lūn-bûn

@nan

2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Salmeterol and fluticasone pro ...... obstructive pulmonary disease

@ast

Salmeterol and fluticasone pro ...... obstructive pulmonary disease

@en

type

label

Salmeterol and fluticasone pro ...... obstructive pulmonary disease

@ast

Salmeterol and fluticasone pro ...... obstructive pulmonary disease

@en

prefLabel

Salmeterol and fluticasone pro ...... obstructive pulmonary disease

@ast

Salmeterol and fluticasone pro ...... obstructive pulmonary disease

@en

P1433

Q29618681-5CC8B0AC-9957-45FF-8010-03CD8C911890

P1476

Q29618681-6636D041-3EDF-4028-899B-E3F80BE6A49C

P2093

Q29618681-341576C1-B78F-49C9-88A0-955AA53B1C42

Q29618681-452D10E6-3217-431E-A9B6-0D31BE5FF4C0

Q29618681-51EB5E1D-A5C8-4B06-8760-2594A7CC935F

Q29618681-62FD1267-7DAE-4FF5-937F-A5E5FC183952

Q29618681-A975F315-4827-4146-839C-31DA103F39F1

Q29618681-B99B4F41-46E6-4D25-8E9E-A4196EF86571

Q29618681-BB33A998-AD40-4AFD-B5E7-3EAD83F659C2

Q29618681-F488DE9A-7531-4DFD-B8BB-65A950AE7920

P304

Q29618681-61430D0E-8FEE-4C96-8251-EA9887741641

P31

Q29618681-2ACF5E57-A751-409E-99AE-9876037FC2B3

P3181

Q29618681-DF1CD1AA-DB1C-4D94-A3BC-5A73782DD872

P356

Q29618681-D6B6BBB9-D6A4-4BCD-8119-CF9A882A46F5

P407

Q29618681-4CC85FC7-E9FA-4EA7-B0FE-A874470D08AA

P433

Q29618681-07334190-807F-494F-95DB-7489AC879544

P478

Q29618681-AADFFCA9-46E3-430F-9914-D5D2A5159C3B

P50

Q29618681-1BEDD69F-6599-468F-AFD3-4BAD6B67E810

P577

Q29618681-11D8F9B4-E6D2-42DA-85BC-487E740E02DE

P698

Q29618681-8CA3BDC9-6FAA-4844-B0D4-395AE9A62FC3

P921

Q29618681-088E7D10-1F62-4C7E-89FB-5E802E680F57

P3181

P356

P1433

The New England Journal of Medicine

P1476

Salmeterol and fluticasone pro ...... obstructive pulmonary disease

@en

P2093

Bartolome Celli

http://www.w3.org/2001/XMLSchema#string

Christine Jenkins

http://www.w3.org/2001/XMLSchema#string

Gary T Ferguson

http://www.w3.org/2001/XMLSchema#string

Julie A Anderson

http://www.w3.org/2001/XMLSchema#string

Julie C Yates

http://www.w3.org/2001/XMLSchema#string

Paul W Jones

http://www.w3.org/2001/XMLSchema#string

Peter M A Calverley

http://www.w3.org/2001/XMLSchema#string

TORCH investigators

http://www.w3.org/2001/XMLSchema#string

P304

775-789

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

279454

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA063070

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

356

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17314337

http://www.w3.org/2001/XMLSchema#string

P921

chronic obstructive pulmonary disease